Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Exarafenib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kinnate Sells Pan-RAF Inhibitor Exarafenib To Pierre Fabre
    Kinnate Sells Pan-RAF Inhibitor Exarafenib To Pierre Fabre

    05 Mar 2024

    // PRESS RELEASE

    https://www.pierre-fabre.com/en/press_release/kinnate-biopharma-inc-sells-its-investigational-pan-raf-inhibitor-exarafenib-to

    PRESS RELEASE
    05 Mar 2024
    Share Share
    Kinnate Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre
    Kinnate Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre

    01 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/03/01/2838802/0/en/Kinnate-Biopharma-Inc-Sells-Its-Investigational-Pan-RAF-Inhibitor-Exarafenib-to-Pierre-Fabre-Laboratories.html

    GLOBENEWSWIRE
    01 Mar 2024
    Share Share
    First Report of +ve Dose Escalation Data Supports Best-in-Class Exarafenib
    First Report of +ve Dose Escalation Data Supports Best-in-Class Exarafenib

    17 Apr 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/04/17/2648391/0/en/First-Report-of-Positive-Dose-Escalation-Data-Supports-Best-in-Class-Profile-for-Investigational-Exarafenib-as-a-Single-Agent-and-in-Combination-with-Binimetinib-in-BRAF-altered-Ca.html

    GLOBENEWSWIRE
    17 Apr 2023
    Share Share